Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE)

📖 Top 20% JournalAug 28, 2025Advances in therapy

Weight Loss with Semaglutide and Tirzepatide in People with Overweight or Obesity Without Diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

After 1 year, mean weight loss was -14.6 kg for semaglutide 2.4 mg and -17.2 kg for tirzepatide.

Both medications were assessed in patients with overweight or obesity without type 2 diabetes.
The percent weight loss from baseline was -14.1% for semaglutide 2.4 mg and -16.5% for tirzepatide.
Most patients on semaglutide (83.5%) achieved the maximum dose of 2.4 mg, while only 25.9% of tirzepatide patients reached the maximum dose of 15 mg.
Baseline characteristics, including mean age and gender distribution, were similar between the two treatment groups.

AI simplified

INTRODUCTION: Semaglutide 2.4 mg injection (Wegovy), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved by the US Food and Drug Administration for weight management in June 2021. Tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, was approved for type 2 diabetes mellitus (T2DM; Mounjaro) in May 2022 and weight management (Zepbound) in November 2023. Due to limited data on the long-term effectiveness of these medications, this study assessed real-world weight loss with semaglutide 2.4 mg or tirzepatide after 1 year in patients with overweight or obesity and without T2DM. ® ® ®

METHODS: This retrospective cohort study included adults with overweight or obesity and ≥ 1 pharmacy claim for semaglutide 2.4 mg or tirzepatide in the US Komodo Health database between June 4, 2021, and December 15, 2023. Patients had continuous enrollment for 1 year before (baseline period) and 1 year after (follow-up period) the index date (date of treatment initiation) and persistence on therapy (no gap of > 30 days' supply) during follow-up. Patients with T2DM at baseline were excluded. Weight change from index to 1 year was descriptively assessed.

RESULTS: Overall, 9916 patients were included (semaglutide 2.4 mg, n = 6794; tirzepatide, n = 3122). Baseline characteristics were descriptively similar for semaglutide 2.4 mg and tirzepatide: mean age was 47.8 and 49.5 years, 79.8% and 77.9% were female, and mean index weight was 104.5 and 104.9 kg, respectively. After 1 year of follow-up, the mean weight loss from baseline with semaglutide 2.4 mg and tirzepatide was - 14.6 and - 17.2 kg, respectively, with percent weight loss of - 14.1% and - 16.5%. Most (83.5%) patients treated with semaglutide 2.4 mg reached the maximum dose (2.4 mg), while 25.9% of patients treated with tirzepatide reached the maximum dose (15 mg).

CONCLUSION: Findings suggest semaglutide 2.4 mg and tirzepatide are used in descriptively similar populations and both resulted in clinically meaningful weight loss after 1 year of treatment.

Key numbers

-14.1%

Mean Weight Loss with Semaglutide 2.4 mg

Weight change after 1 year of treatment

-16.5%

Mean Weight Loss with Tirzepatide

Weight change after 1 year of treatment

9916

Total Patients Included

Total number of patients treated with either medication

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (HTML) ↗View full text (PDF) ↗

Abstract

Key numbers

Full Text

Related papers